中金发布研报称，维持翰森制药(03692.HK)“跑赢行业”评级，目标价52.00港元，对应2026年及2027年市盈率分别为43.9倍及42.3倍，潜在上行空间为51.25%。10月19日，翰森制药公告与罗氏达成ADC多项目战略合作及授权协议，涵盖 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results